A Study of XL184 (Cabozantinib) in Endometrial Cancer

Official Title

A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer


This is a phase 2 study to determine the efficacy of a new investigational drug called XL184 (also called cabozantinib) in treating patients with recurrent or metastatic endometrial cancer. The surface of each cell contains proteins (called receptors) that help to send and receive signals from the body in order for the cell to function such as cell growth, survival, and death. Sometimes, the receptors become overactive and will continue sending signals for cells, especially cancer cells, to uncontrollably grow and divide. The new investigational drug XL184 blocks a group of receptors called receptor tyrosine kinases (RTKs) that are thought to be important in the growth and spread of tumour cells. It is believed that by blocking these receptors from receiving signals for the tumour cells to grow, the tumour may stop growing or shrink. The purpose of the study is to determine the usefulness of the study drug.

Trial Description

Primary Outcome:

  • Number of participants with an objective response
  • Progression-free-survival of each participant
Secondary Outcome:
  • Number of participants with clinical response who have c-met amplification and/or high levels of soluble circulating angiogenic factors.

Reviewed by OCREB.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society